STAAR Surgical (NASDAQ:STAA) Major Shareholder Acquires $553,925.40 in Stock

STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. purchased 31,780 shares of STAAR Surgical stock in a transaction that occurred on Wednesday, April 2nd. The shares were acquired at an average price of $17.43 per share, with a total value of $553,925.40. Following the acquisition, the insider now directly owns 12,487,044 shares of the company's stock, valued at $217,649,176.92. This trade represents a 0.26 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 7th, Broadwood Partners, L.P. purchased 138,054 shares of STAAR Surgical stock. The stock was acquired at an average price of $15.61 per share, for a total transaction of $2,155,022.94.
• On Friday, April 4th, Broadwood Partners, L.P. acquired 497,631 shares of STAAR Surgical stock. The stock was bought at an average price of $15.91 per share, for a total transaction of $7,917,309.21.
• On Monday, March 31st, Broadwood Partners, L.P. bought 22,189 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.46 per share, for a total transaction of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. purchased 3,620 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was bought at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The stock was bought at an average cost of $15.49 per share, with a total value of $565,880.68.

STAAR Surgical Price Performance

Shares of NASDAQ STAA traded up $0.22 during mid-day trading on Monday, hitting $16.14. 1,526,031 shares of the stock traded hands, compared to its average volume of 784,406. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68. The firm has a 50 day simple moving average of $18.65 and a two-hundred day simple moving average of $24.55. The company has a market cap of $796.11 million, a PE ratio of -39.37 and a beta of 0.75.

Remove Ads

Institutional Trading of STAAR Surgical

A number of hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in STAAR Surgical by 4,086.0% in the 1st quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier's stock valued at $258,000 after buying an additional 14,301 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in STAAR Surgical by 13.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier's stock valued at $2,684,000 after acquiring an additional 13,075 shares during the period. Voloridge Investment Management LLC increased its position in STAAR Surgical by 9.4% in the 4th quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier's stock valued at $7,196,000 after acquiring an additional 25,350 shares during the period. Squarepoint Ops LLC raised its stake in shares of STAAR Surgical by 81.3% during the fourth quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier's stock valued at $2,844,000 after acquiring an additional 52,488 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of STAAR Surgical during the fourth quarter worth $502,000. 96.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on STAA shares. Stifel Nicolaus decreased their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of STAAR Surgical in a research report on Thursday, February 27th. Mizuho cut STAAR Surgical from an "outperform" rating to a "neutral" rating and cut their target price for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. BTIG Research lowered STAAR Surgical from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th. Finally, William Blair downgraded STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.